JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koppe, M. J.
Right arrow Articles by Bleichrodt, R. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koppe, M. J.
Right arrow Articles by Bleichrodt, R. P.

Radioimmunotherapy Is an Effective Adjuvant Treatment After Cytoreductive Surgery of Experimental Colonic Peritoneal Carcinomatosis

Manuel J. Koppe, MD1,2, Thijs Hendriks, PhD1, Otto C. Boerman, PhD2, Wim J.G. Oyen, MD, PhD2 and Robert P. Bleichrodt, MD, PhD1

1 Department of Surgery, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands; and 2 Department of Nuclear Medicine, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands


Figure 1
View larger version (14K):

[in a new window]
  		FIGURE 1.  Biodistribution of 125I-MG1, 111In-MG1, or 177Lu-MG1 in Wag/Rij rats with small peritoneal CC-531 metastases. Note that biodistribution of 177Lu-MG1 was determined in a separate experiment.

 

Figure 2
View larger version (8K):

[in a new window]
  		FIGURE 2.  Tumor weight at dissection of Wag/Rij rats with small peritoneal CC-531 metastases 26 d after treatment with PBS–0.5% BSA (control rats), unlabeled MG1, or 177Lu-MG1. Note that these rats did not undergo surgery.

 

Figure 3
View larger version (39K):

[in a new window]
  		FIGURE 3.  Macroscopic appearance of intraperitoneally growing CC-531 tumors in Wag/Rij rats. (A) Multiple tumor deposits in greater omentum. (B) Two tumor deposits in liver hilum (arrows). (C) One tumor deposit on mesentery (arrow).

 

Figure 4
View larger version (15K):

[in a new window]
  		FIGURE 4.  Relative body weight of Wag/Rij rats with small peritoneal CC-531 metastases in first month after exploratory laparotomy (EL) only, EL + radioimmunotherapy (RIT), cytoreductive surgery (CS) only, or CS + RIT. Data are expressed as mean ± SEM.

 

Figure 5
View larger version (12K):

[in a new window]
  		FIGURE 5.  Survival curves for Wag/Rij rats with small peritoneal CC-531 metastases after exploratory laparotomy (EL) only, EL + radioimmunotherapy (RIT), cytoreductive surgery (CS) only, or CS + RIT. There was a highly significant trend toward improved survival for rats treated with CS + RIT compared with both CS only and EL + RIT (P = 0.0004 for both trend analyses).

 

Figure 6
View larger version (9K):

[in a new window]
  		FIGURE 6.  (A) Ascites weight found in Wag/Rij rats with small peritoneal CC-531 metastases at time of death after exploratory laparotomy (EL) only, EL + radioimmunotherapy (RIT), cytoreductive surgery (CS) only, or CS + RIT. Differences were not statistically significant (P = 0.2219). (B) Tumor weight found in Wag/Rij rats with small peritoneal CC-531 metastases at time of death after EL only, EL + RIT, CS only, or CS + RIT. Tumor weight of rats treated with EL + RIT was significantly lower compared with that of rats treated with EL only or CS only (P < 0.05). (C) PCI found in Wag/Rij rats with small peritoneal CC-531 metastases at time of death after EL only, EL + RIT, CS only, or CS + RIT. PCI of rats treated with RIT, preceded by either EL or CS, was significantly lower compared with that of rats treated with EL only or CS only (P < 0.05).

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2006 by the Society of Nuclear Medicine.